“Perhaps the most difficult time for the pharmaceutical industry is over.” Wan Yuanmin, fund manager of Rongtong Fund, expressed his sentiments and showed how difficult it was for many pharmaceutical fund managers and Jimin to insist on holding positions in pharmaceuticals for many years. As the bull market for innovative drugs in Hong Kong continues to evolve, this year many citizens have discovered that their pharmaceutical funds, which have been losing money for many years, have begun to make money. Recently, the innovative drug sector of Hong Kong stocks has continued to strengthen, and the investment value of pharmaceutical stocks and pharmaceutical funds has once again attracted market attention. The Securities Times reporter interviewed many fund managers, including Ma Yiwen of Cathay Pacific Fund, Jinhuang of Jingtong Fund, Wan Minyuan of Rongtong Fund, Ouyang Juan of Golden Eagle Fund, Liao Qingyang of Huafu Fund, and Tang Chen of Nuoan Fund to conduct an in-depth analysis of market rebound drivers, main line logic, and track segmentation opportunities throughout the year. Many fund managers believe that the rise in the innovative medicine sector of Hong Kong stocks is not driven by short-term sentiment, but rather a concentrated expression of long-term logic such as policy dividends, industrial upgrading, and global breakthroughs. Although we need to pay attention to the pace of policy implementation and changes in the external environment in the short term, the trend of China's innovative drugs from “following” to “leading” has gradually been established, and the revaluation process in the global industrial chain is on the rise. For investors, it is the key to grasping the main line of integrating innovative drugs into overseas markets and technology, balancing the logic of repairing undervaluations and realizing performance, or sharing the dividends of industrial upgrading.

“Perhaps the most difficult time for the pharmaceutical industry is over.” Wan Yuanmin, fund manager of Rongtong Fund, expressed his sentiments and showed how difficult it was for many pharmaceutical fund managers and Jimin to insist on holding positions in pharmaceuticals for many years. As the bull market for innovative drugs in Hong Kong continues to evolve, this year many citizens have discovered that their pharmaceutical funds, which have been losing money for many years, have begun to make money. Recently, the innovative drug sector of Hong Kong stocks has continued to strengthen, and the investment value of pharmaceutical stocks and pharmaceutical funds has once again attracted market attention. The Securities Times reporter interviewed many fund managers, including Ma Yiwen of Cathay Pacific Fund, Jinhuang of Jingtong Fund, Wan Minyuan of Rongtong Fund, Ouyang Juan of Golden Eagle Fund, Liao Qingyang of Huafu Fund, and Tang Chen of Nuoan Fund to conduct an in-depth analysis of market rebound drivers, main line logic, and track segmentation opportunities throughout the year. Many fund managers believe that the rise in the innovative medicine sector of Hong Kong stocks is not driven by short-term sentiment, but rather a concentrated expression of long-term logic such as policy dividends, industrial upgrading, and global breakthroughs. Although we need to pay attention to the pace of policy implementation and changes in the external environment in the short term, the trend of China's innovative drugs from “following” to “leading” has gradually been established, and the revaluation process in the global industrial chain is on the rise. For investors, it is the key to grasping the main line of integrating innovative drugs into overseas markets and technology, balancing the logic of repairing undervaluations and realizing performance, or sharing the dividends of industrial upgrading.